199 related articles for article (PubMed ID: 29056657)
1. Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN).
Argyriou AA
Toxics; 2015 May; 3(2):187-197. PubMed ID: 29056657
[TBL] [Abstract][Full Text] [Related]
2. Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity.
Velasco R; Alemany M; Villagrán M; Argyriou AA
J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357136
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Kalofonos HP
J Peripher Nerv Syst; 2021 Mar; 26(1):43-48. PubMed ID: 33345432
[TBL] [Abstract][Full Text] [Related]
4. Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Psimaras D; Bruna J; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):178-183. PubMed ID: 32277545
[TBL] [Abstract][Full Text] [Related]
5. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
6. Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Antonacopoulou AG; Alberti P; Briani C; Bruna J; Velasco R; Anastopoulou GG; Park SB; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2019 Dec; 24(4):298-303. PubMed ID: 31486252
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-induced Peripheral Neuropathy in South Indian Cancer Patients: A Prospective Study in Digestive Tract Cancer Patients.
Palugulla S; Dkhar SA; Kayal S; Narayan SK
Indian J Med Paediatr Oncol; 2017; 38(4):502-507. PubMed ID: 29333020
[TBL] [Abstract][Full Text] [Related]
8. The Incidence of Oxaliplatin-Induced Peripheral Neurotoxicity at Khartoum Oncology Hospital: A Cross-Sectional Survey.
Ali NT; Mohamed AA; Yousef BA
Asia Pac J Oncol Nurs; 2020; 7(3):266-272. PubMed ID: 32642498
[TBL] [Abstract][Full Text] [Related]
9. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
[TBL] [Abstract][Full Text] [Related]
10. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
[TBL] [Abstract][Full Text] [Related]
11. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.
Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G
J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589
[TBL] [Abstract][Full Text] [Related]
13. Non-randomized preliminary study of an education and elastic-band resistance exercise program on severity of neuropathy, physical function, muscle strength and endurance & quality of life in colorectal cancer patients experiencing oxaliplatin-induced peripheral neuropathy.
Chen SC; Huang HP; Huang WS; Lin YC; Chu TP; Beaton RD; Jane SW
Eur J Oncol Nurs; 2020 Dec; 49():101834. PubMed ID: 33120223
[TBL] [Abstract][Full Text] [Related]
14. Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial.
de Andrade DC; Jacobsen Teixeira M; Galhardoni R; Ferreira KSL; Braz Mileno P; Scisci N; Zandonai A; Teixeira WGJ; Saragiotto DF; Silva V; Raicher I; Cury RG; Macarenco R; Otto Heise C; Wilson Iervolino Brotto M; Andrade de Mello A; Zini Megale M; Henrique Curti Dourado L; Mendes Bahia L; Lilian Rodrigues A; Parravano D; Tizue Fukushima J; Lefaucheur JP; Bouhassira D; Sobroza E; Riechelmann RP; Hoff PM; ; Valério da Silva F; Chile T; Dale CS; Nebuloni D; Senna L; Brentani H; Pagano RL; de Souza ÂM
Oncologist; 2017 Oct; 22(10):1154-e105. PubMed ID: 28652279
[TBL] [Abstract][Full Text] [Related]
15. Association of Voltage-Gated Sodium Channel Genetic Polymorphisms with Oxaliplatin-Induced Chronic Peripheral Neuropathy in South Indian Cancer Patients.
Palugulla S; Thakkar DN; Kayal S; Narayan SK; Dkhar SA
Asian Pac J Cancer Prev; 2017 Nov; 18(11):3157-3165. PubMed ID: 29172294
[TBL] [Abstract][Full Text] [Related]
16. TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17β-Estradiol Treatment.
Pan Y; Chen F; Huang S; Cai Z; Lan H; Tong Y; Yu X; Zhao G
Curr Neurovasc Res; 2016; 13(4):309-317. PubMed ID: 27262300
[TBL] [Abstract][Full Text] [Related]
17. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.
Argyriou AA; Briani C; Cavaletti G; Bruna J; Alberti P; Velasco R; Lonardi S; Cortinovis D; Cazzaniga M; Campagnolo M; Santos C; Kalofonos HP
Eur J Neurol; 2013 May; 20(5):788-94. PubMed ID: 23252594
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
Bruna J; Videla S; Argyriou AA; Velasco R; Villoria J; Santos C; Nadal C; Cavaletti G; Alberti P; Briani C; Kalofonos HP; Cortinovis D; Sust M; Vaqué A; Klein T; Plata-Salamán C
Neurotherapeutics; 2018 Jan; 15(1):178-189. PubMed ID: 28924870
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of oxaliplatin-associated neurotoxicity.
Grothey A
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
[TBL] [Abstract][Full Text] [Related]
20. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
Argyriou AA; Velasco R; Briani C; Cavaletti G; Bruna J; Alberti P; Cacciavillani M; Lonardi S; Santos C; Cortinovis D; Cazzaniga M; Kalofonos HP
Ann Oncol; 2012 Dec; 23(12):3116-3122. PubMed ID: 22865779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
